trial

A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults

NCTId NCT05622201
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Active Not Recruiting
Enrollment 123 (actual)
Sponsored by Region Örebro County
Primary completion 2026-08-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Active Not Recruiting
Enrollment
123 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-03-21
Primary completion
2026-08-30
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Rituximab

Sponsors

Region Örebro CountyLead Sponsor

Investigators

1
Susanne Bejerot, MD, PhDPrincipal Investigator

Sites

1 total
Örebro, Sweden

Linked catalysts

1
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults — primary completion2026-08-30

Facts & assertions

4 sourced
Enrollment
123
Phase
PHASE2
Primary Completion Date
2026-08-30
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Rituximab
drug
lead_sponsor
Region Örebro County
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Psychotic Disorders
indication
investigator
Susanne Bejerot, MD, PhD
person